Yi Shi
Managing Director & Founder @ Lilly Asia Ventures
Yi Shi is a Series B investor at Lilly Asia Ventures focused on Biotechnology and Medical. Dr. Yi Shi joined Lilly Asian Ventures in 2007 as a Managing Director based in Shanghai, China. Prior to the current assignment, he worked in various roles with increasing responsibility over six years at Eli Lilly and Company. His experience includes leading the development of a comprehensive investment strategy for China as well as negotiatingmultiple biotechnology and pre-clinical deals world-wide.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Yi Shi invests in
Stages Yi Shi invests in
Countries Yi Shi invests in
Investment Focus
Industry
- Biotechnology 7 (50%)
- Medical 3 (21%)
- Biopharma 3 (21%)
- Health Care 3 (21%)
- Pharmaceutical 2 (14%)
Stage
- Series B 5 (36%)
- Series A 3 (21%)
- Angel 1 (7%)
- Series C 1 (7%)
- Series D 1 (7%)
Country
- China 6 (43%)
- United States 2 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SciNeuro
|
SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases. | $53M / Venture - Series Unknown / Dec 04, 2025 | |
Ronovo Surgical
|
Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery. | $67M / Series D / Sep 04, 2025 | |
OTR Therapeutics
|
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems. | $100M / Series A / Jun 01, 2025 | |
|
Ronovo Surgical
|
Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery. | $28.3M / Series B / Aug 30, 2023 | |
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $29.1M / Series C / Apr 12, 2023 | |
Neukio Biotherapeutics
|
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world. | $50M / Series A / Sep 02, 2022 | |
|
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $54.5M / Series B / Sep 13, 2021 | |
|
Neukio Biotherapeutics
|
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world. | $40M / Angel / Jul 29, 2021 | |
Duality Biologics
|
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company hasbuilt a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development. | $90M / Series B / May 19, 2021 | |
|
Duality Biologics
|
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company hasbuilt a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development. | $90M / Series B / May 19, 2021 | |
| See all 14 investments → | |||
Co-Investors
About Lilly Asia Ventures
Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities inChina, although they will consider investment opportunities elsewhere in east and south Asia.
Lilly Asia Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jiaxin Li
partner
|
|||
Judith Li
Partner
|
|||
Stella Shi
Venture Partner
|
|||
|
Yi Shi
Managing Director & Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Yi Shi invest in?
Yi Shi invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Yi Shi last invest?
The most recent investment recorded for Yi Shi closed in Dec 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
